Clinical Trial

Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma

Name: Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma — clinical trial record (NCT06837922)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

A randomized, double-blind, placebo-controlled Phase III clinical trial on the efficacy and safety of MG-K10 humanized monoclonal antibody injection in adolescent and adult patients with moderate to severe asthma.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-02-16.

Trial Details

NCT Number	NCT06837922
Lead Sponsor	Shanghai Mabgeek Biotech.Co.Ltd
Conditions	Asthma
Enrollment	504 participants
Start Date	2025-03-25
Primary Completion	2027-11-15 (estimated)
Study Completion	2028-01-15 (estimated)
Updated on ClinicalTrials.gov	2025-04-17